The FDA criticized Meridian for not making the the connection that the defective part might be the source of the problems, a fact the FDA said it "ultimately confirmed." The FDA upbraided Meridian because it didn't widen its own investigation to other potentially affected products and didn't recall EpiPens from the market at that point. For years, Mylan and its Pfizer-made pens were essentially the only product in the epinephrine injector market. Mylan's aggressively marketing and repeated price jumps, however, raised consumer, and eventually legislators' ire.